Companies / RAD

RADIOPHARM THERANOSTICS LIMITED

ASX:RADPharmaceuticals, Biotechnology & Life Sciences
3.93B shares on issueAppendix 2A · as of 28 July 2026$0.014price · delayed—market cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 272% in 24 months; 4 cash raises in 24 months

Cash runway1.1 quarters of funding
Share-count growth (24m)271.5%
Raise cadence (24m)4 cash raises
Options & rights overhang93.4% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

RADIOPHARM THERANOSTICS LIMITED's ordinary share count grew 271.5% between July 2024 and July 2026, to 3.93B shares. The company raised capital four times in the 24-month window for total disclosed proceeds of A$97.3M, most recently a A$18.5M placement in July 2026. Options and rights on issue could convert into 3.67B new shares, equal to 93.4% of the current share count, of which 0% are in the money; the nearest expiry is August 2026. At the March 2026 quarter the company reported A$16.8M in available cash, about 1.1 quarters of funding at its recent spending rate. Three proposed securities issues (Appendix 3B) are pending, the nearest proposed issue date is August 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
93.4%
Max option dilution
0.0%
ITM option dilution
3
Raises · last 12 months
1.1 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 3.93B per Appendix 2A (28 July 2026).
2.46B2.86B3.26BDec 24Sept 25July 26Cash raise · 21 July 2026Cash raise · 15 Oct 2025Cash raise · 14 Oct 2025Cash raise · 9 Jan 2025

Cash runway

1.1 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$16.8M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
28 July 20262A · quoted issueRAD : ORDINARY FULLY PAID3.93BAppendix 2A
30 June 20263G · unquotedORDINARY FULLY PAID3.54BAppendix 3G
30 June 20263H · cancellationRAD : ORDINARY FULLY PAID3.54BAppendix 3H
3 June 20263H · cancellationRAD : ORDINARY FULLY PAID3.54BAppendix 3H
22 Dec 20253H · cancellationRAD : ORDINARY FULLY PAID3.54BAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 3 in the last 12 months

$18.5M
Placement
21 July 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

3 proposed issues pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

93.4%
Total overhang · of current shares
0.0%
In the money · at current price
3.67B
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
12 Dec 2025Riccardo CanevariOther—74.3M—3Y notice
12 Dec 2025Paul HopperOther—18.1M—3Y notice
12 Dec 2025Ian TurnerOther—6.8M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026Notice Under Section 708A
28 July 2026Application for quotation of securities - RAD
24 July 2026$PReinstatement to Quotation
24 July 2026Investor Presentation - Capital Raising
24 July 2026Proposed issue of securities - RAD
24 July 2026Proposed issue of securities - RAD
24 July 2026$PRAD completes A$12.5 M placement and launches A$6 M SPP
23 July 2026$PSuspension from Quotation
21 July 2026$PTrading Halt
21 July 2026$PRAD Achieves Partial Response in Phase 1 Trial of RAD204
21 July 2026$PRAD Announces Positive Phase 2b Trial Results of RAD 101
3 July 2026Radiopharm Receives $5.9M R&D Tax Incentive
30 June 2026Notification regarding unquoted securities - RAD
30 June 2026Notification of cessation of securities - RAD
3 June 2026Notification of cessation of securities - RAD
30 Apr 2026Financial Services and Company Secretary Changes
22 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
19 Apr 2026RAD Initial Findings from Phase 1 177Lu-RAD202 Trial
15 Apr 2026$PRAD Completes Enrollment in Phase 2b Trial of RAD 101
7 Apr 2026$PRAD202 Phase 1 HEAT Trial Advances to Dose Level 3

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.